Skip to main content

“After two exceptionally dynamic years, we delivered another year of strong results. Despite the challenging operating environment, our growth was broad-based across the portfolio and the geographies, and we see us a good year ahead of our mid-term plan. While growth in the lab division was even slightly stronger than forecast, the bioprocess division was influenced by the expected normalization of demand, a process that is expected to continue for several quarters.

As we look ahead, we see that the strong fundamental growth drivers in our markets remain unchanged. Demand for biopharmaceuticals is on the rise in all indication areas and regions, and at the same time the biotech industry is in an extraordinarily innovative phase. We are excellently positioned to support our customers in their endeavors and to seize the opportunities that arise from this. Substantial investments into capacities and acquisitions that expand our capabilities will therefore remain part of our growth strategy.”

Chairman’s Message

Sales revenue


in constant FX: +15.0%

Underlying EBITDA



Order intake


in constant FX: -10.1%




Market capitalization



Group Business Development and Divisions

Following extraordinary growth in 2020 and 2021, the life science group Sartorius again outperformed the market in fiscal 2022, achieving its targets for sales revenue and profitability. Both divisions contributed to this development and, according to preliminary figures, recorded double-digit percentage growth in sales revenue and earnings year-over-year.

Group Business Development

Bioprocess Solutions

In the Bioprocess Solutions Division, Sartorius offers a broad product portfolio that covers all steps in the production of a biopharmaceutical. The company has held leading market positions for years in its core technologies, such as filtration, fermentation, cell cultivation and fluid management.

Business Development of Bioprocess Solutions

Lab Products & Services

The Lab Products & Services Division offers laboratories in the pharmaceutical and biopharmaceutical industries as well as at academic research institutes innovative solutions for bioanalytics, in addition to premium laboratory products, consumables and services. Sartorius is among the market leaders in laboratory balances, pipettes and lab consumables.

Business Development of Lab Products & Services


Following the exceptionally strong previous years, Sartorius expects further growth in 2023 despite demand normalization and anticipated further declines in the Covid-19-related business. In addition, management adjusted the medium-term sales revenue forecast in light of increased inflation and associated price adjustments.



Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1 percentage point to growth. The Group’s underlying EBITDA margin should be around the level of the prior year (33.8 percent).



Strategy and Long-Term Targets

Sartorius now expects sales revenue of around 5.5 billion euros in 2025 (previously around 5 billion euros). The forecast for the Group’s underlying EBITDA margin in 2025 remains unchanged at around 34 percent.